Glaukos Announces First Quarter 2024 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2024. Key highlights include: Record net sales of $85.6 million in Q1 2024 increased 16% year-over-year. Glaucoma record net sales of $67.2 million in Q1 2024 increased 20% year-over-year. Corneal